Audit: QRS - GHRP-2 for Health & Longevity
Audit conducted on 09/08/2026 16:28 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 91 |
| Passed | 81 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every span traced to ER: protocol cells to ER Therapeutic Protocol (lines 393, 405, 409, 377); time cells to ER lines 407, 449; benefit/risk tiers to ER Expected Benefits / Potential Risks & Side Effects headings; all 10 markers and their targets/rationales to the ER Monitoring Protocol & Defining Success table (lines 481–490). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | At-A-Glance preserves the ER Conclusion’s “No study of muscle, fat, bone, strength, or long-term outcome in healthy adults exists” (ER line 532). No cautious ER phrasing is dropped or hardened. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications remain contraindications; “Pregnancy and lactation” carried as a stop item, not a caution. No tier promotion or demotion against the ER. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Stop items come only from the ER’s “Populations who should avoid this intervention” bullet (ER line 363); caution items only from the remaining Key Interactions & Contraindications bullets. No Benefit-Modifying Factors or Risk-Modifying Factors content leaked into the gates. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, no citations, no NCT identifiers, no expert names anywhere in the QRS body. Drug names in the interactions gate (sermorelin, tesamorelin, CJC-1295, ipamorelin, octreotide, etc.) all appear in the same ER bullets. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind in the QRS. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | The ER’s measured, sceptical register (“the record rather than a verdict”) is carried through; the QRS reports the strong hormonal signal alongside the absent outcome data, exactly as the ER does. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified targets, dose, timing, and a monitoring cadence give the reader something actionable; language stays neutral and non-alarmist while remaining candid about the evidence gap. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is presented as what protocols and evidence describe (e.g., “split dosing is standard”, “Prudent surveillance given sustained IGF-1 elevation”), not as instruction to an individual. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No prescriptive verbs, no imperatives directed at a person; the footer disclaimer is the template’s own. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Text scan finds no instance of “recommend”, “advis”, “should”, or “must” anywhere in the rendered body. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | Text scan finds no second-person pronouns (“you”, “your”) in the rendered body. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms retained are the ER’s own verbatim labels required by items 4.2/4.3 (e.g., “Comprehensive metabolic panel with liver enzymes”); no jargon is added beyond the ER. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate and tier entries are bare noun phrases; ER mechanistic rationale, glosses, and magnitudes are stripped throughout. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by the same scan as 2.6 — no direct address anywhere. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | The sheet assumes a reader who will source, dose, and blood-test — 10-marker panel, functional (not conventional) ranges, off-cycle reassessment. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Fasted injection windows, 1–3 daily subcutaneous administrations, weekly home blood pressure and weight, and a repeating fasting panel are all presented without hedging on inconvenience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Functional biomarker targets (fasting insulin 2–5 µIU/mL, HbA1c 4.8–5.3%) are tighter than conventional clinical thresholds, which is a specifically optimiser-facing frame. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Appetite stimulation appears as a High benefit only “in low-intake states” and simultaneously as a High risk (“increased appetite and weight gain”), mirroring the ER’s explicit split for a restraint-oriented readership. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | Text scan finds no occurrence of “anti-aging” or “anti-ageing” in the QRS. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “Subcutaneous”, “insulin syringe”, “resistance training”, “injection-site reactions” used throughout; no “pill”, “shot”, or similar consumer register found. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All present verbatim: “Protocol” (line 445), “Time to effect” (491), “Benefits” (540), “Risk & Side Effects” (612), “Monitoring” (646), “Qualitative Assessment” (819), “Contraindications” (573), “Key Interactions” (591), tier labels in both tiered cards, and “Marker”/”Target”/”Why” (650–652). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Parsed source contains 70 data-qrs-var spans covering the complete variable set: page_title, header_topic/subline_date/subline_model, at_a_glance, action_1–3 (label/value/sub), time_1–3 (label/value/sub), benefits_high/medium/low/speculative, stop_items, caution_items, risks_high/medium/low/speculative, marker_1–10 (name/target/why), monitoring_cadence, qualitative_item_1–6. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Every one of the 70 spans is addressed by a checklist item in sections 6–15; no unaddressed span exists to have been altered. The non-variable website="…" hooks (evidence_review, audit, full_review) are left untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section feeding the QRS is empty — every benefit tier, risk tier, gate, marker row, and qualitative marker has ER content. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | All six qualitative labels are verbatim ER bold labels (“Sleep depth and morning restoration”, “Appetite and eating control”, “Recovery between training sessions”, “Joint comfort and hand symptoms”, “Libido and sexual function”, “Energy, mood, and cognitive clarity”; ER lines 494–504). Marker names match the ER table’s biomarker column. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Marker names carry the ER’s own names (“Fasting lipid panel”, “Thyroid panel (TSH, free T4, free T3)”, “PSA, men over 45”); only definitional glosses in parentheses (“(insulin-like growth factor 1)”, “(glycated haemoglobin)”) are dropped, not the labels themselves. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Character scan of the rendered body returns zero emoji codepoints; the ER’s 🟩/🟥/🟨/⚠️ markers are all stripped. Tier signalling is by CSS class (.benefits, .risks) and bold tier labels. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | The @page A4 print rule and single .sheet container are intact, and every over-long ER section was condensed rather than carried over: benefit/risk tiers reduced to semicolon-joined headings, gate items reduced to bare facts with glosses stripped, marker rationales cut to one clause each. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14: the metadata comment immediately follows <!doctype html> on line 1 and precedes the template comment on line 16 and <html> on line 17. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- on line 3, closing --- on line 13; the preamble “QRS — Metadata (invisible, parsed by audit tooling)” sits before the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | It is inside an HTML comment outside <html>; no element in the body repeats the creation date, prompt version, git user, or issue number. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:04" is quoted, and it contains a colon requiring YAML quoting. All other values are bare and untrimmed of nothing. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: ghrp_2_2026-0807-1329_Opus_ER.md, matching the ER’s own filename frontmatter value. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0809-1618 — correct YYYY-MMDD-HHMM form. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version, no qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” = nickname + version number, no context-window or tier qualifier appended. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: ghrp_2_2026-0807-1329_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all ten keys: no stray whitespace and no unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: GHRP-2 for Health & Longevity - Quick Reference Sheet — ER canonical_topic is “GHRP-2 for Health & Longevity”, correctly entity-encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: GHRP-2 for Health & Longevity, no suffix, correctly encoded. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 08/09/2026, the correct MM/DD/YYYY rendering of qrs_creation_date: 2026-0809-1618. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: Opus 5, matching qrs_creator_ai_fullname. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header holds only the title and the template subline; the ER’s long “Also known as” list (Pralmorelin, KP-102, GPA-748, …) is not carried over, and no badge or audit stamp is present. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Four sentences distilling ER lines 530–532: mechanism, the two best-documented effects, the single licensed use, and the evidence gap. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | Programmatic word count: 58 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Bursts/pituitary → ER 530; GH and “liver growth factor” held over a month → ER 530; marked hunger increase → ER 530; Japanese one-time test licence → ER 530; no muscle/fat/bone/strength/long-term study → ER 532. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms at all: IGF-1 is rendered as “liver growth factor” and GHSR-1a agonism as “prompts the pituitary gland to release its own growth hormone in bursts”, mirroring the ER Conclusion’s own plain-language substitutions. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No study name, year, cohort size, or p-value appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | “stay raised for at least a month” and “hunger rises sharply” are qualitative; no percentages, fold-changes, or confidence intervals. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Every stop item traces to the “Populations who should avoid this intervention” bullet at ER line 363. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All eleven ER contraindications are present and none is invented: malignancy, diabetic retinopathy, prolactinoma/high prolactin, acromegaly, pregnancy/lactation, under-18 open growth plates, adrenal insufficiency, NYHA III–IV heart failure, eGFR <30, uncontrolled T2D, WADA-tested athletes. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Lines 576–586: eleven discrete <li> elements inside the stop_items span; HTML parses with balanced tags. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s explanatory glosses are all stripped (e.g., the retinopathy gloss “diabetes-related damage to the light-sensing layer…”, the acromegaly gloss, the eGFR gloss). The only en-dash present is inside the range “Class III–IV”, not a trailing clause. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “(within 5 years, excluding basal cell skin cancer)”, “(outside specialist paediatric endocrine supervision)”, “Class III–IV”, “below 30 mL/min/1.73 m²”, “(HbA1c above 8.0%)” all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER contraindication bullet contains no ranking notation; its only symbols are threshold comparators expressed in words (“above 8.0%”, “below 30”). |
| 8.7 | If no [stop_items] are present the section is left empty | N/A | Eleven stop items are present. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine caution items map one-to-one onto ER bullets at lines 345–361. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Insulin/secretagogues, glucocorticoids, thyroid/oestrogen/testosterone, somatostatin analogues, dopamine agents, other GH-axis agents, NSAIDs, additive GH supplements, and the carbohydrate/protein plus niacin item — with no overlap against the eleven stop items. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Lines 594–602: nine discrete <li> elements inside the caution_items span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s severity tags (“— caution, monitor”, “— absolute pharmacological antagonism”) and its consequence/mitigation sentences are all removed; no dash-trailing clause survives in any item. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Named examples preserved throughout: glimepiride/glipizide/glyburide, prednisone/dexamethasone/hydrocortisone, octreotide/lanreotide, risperidone/haloperidol/amisulpride/metoclopramide, cabergoline/bromocriptine, the full GH-axis agent list, ibuprofen/naproxen, and the amino-acid list; the “roughly two hours” time window is kept. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER interaction bullets use plain comma-separated drug lists with no ranking notation. |
| 9.7 | If no [caution_items] are present the section is left empty | N/A | Nine caution items are present. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Dose/frequency/route from ER line 393, split-dosing and agonist ceiling from ER lines 377 and 409, timing from ER line 405. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, Frequency, and Timing are precisely the three variables the ER’s dominant clinic protocol is specified by. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies well more than three actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans carry substantive ER-derived content — e.g. action_1_sub “Subcutaneous into abdominal fat with a 29–31 gauge insulin syringe; roughly 1 µg/kg” against ER line 393; no placeholder text remains. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Growth hormone (15–30 min), IGF-1 (24 hours), and body composition (months) — the three the ER’s “Time to effect” bullet at line 449 leads with. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Slots 1 and 2 map to the ER’s High-tier benefit “Sustained Elevation of Growth Hormone and IGF-1”; slot 3 maps to the Low-tier “Gains in Fat-Free Mass”. Ordering runs from the largest-magnitude benefit downward. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies five time-to-effect aspects; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans populated and traceable: peak/return window to ER lines 407 and 449, the 30-day IGF-1 plateau to ER line 449, and the twelve-month lean-mass-without-strength result to ER line 449. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All twelve entries correspond exactly to the twelve ER Expected Benefits sub-headings across the four tiers. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present at lines 542, 548, 554, 560, each with the matching bold tier label. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a semicolon-joined list of bare ER headings; the ER’s Magnitude: lines (>3-fold GH, 35.9 ± 10.9% intake, +1.1 kg fat-free mass, 95% CIs) and mechanism paragraphs are entirely absent. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear anywhere in the four benefit spans. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers have ER content, so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All fourteen entries correspond exactly to the fourteen ER sub-headings across the four risk tiers. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present at lines 614, 621, 628, 634 with the matching bold tier labels. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Bare heading phrases only; the ER’s quantified magnitudes (0.3 mmol/L glucose rise, 47 nmol/L cortisol rise, 2.7 kg weight gain, 45 of 61 studies) and mechanism text are all dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear anywhere in the four risk spans; the ER’s inline glosses such as “(fluid swelling)” and “(chronically high prolactin)” are removed. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four risk tiers have ER content, so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Every row is drawn from the ER Monitoring Protocol & Defining Success biomarker table at lines 481–490. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All ten ER table rows are present in ER order: IGF-1, fasting glucose, fasting insulin, HbA1c, prolactin, morning cortisol, fasting lipid panel, comprehensive metabolic panel with liver enzymes, thyroid panel, PSA over 45; the ER’s home measures (blood pressure, body weight) are carried in the cadence line. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 809–812 reproduce the ER’s front-loaded cadence (ER line 477): baseline, 6 weeks, 12 weeks, then every 3–6 months plus each off-cycle break, with weekly home blood pressure and weight. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All six entries come from the qualitative-marker list at ER lines 494–504. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | Six of six carried across with verbatim bold labels and condensed descriptors; none omitted. |
Issues 09/08/2026 16:28
Pass rate 100.00%. No issues found.